DK2474544T3 - Terapeutisk middel mod angstlidelser - Google Patents

Terapeutisk middel mod angstlidelser Download PDF

Info

Publication number
DK2474544T3
DK2474544T3 DK10813754.8T DK10813754T DK2474544T3 DK 2474544 T3 DK2474544 T3 DK 2474544T3 DK 10813754 T DK10813754 T DK 10813754T DK 2474544 T3 DK2474544 T3 DK 2474544T3
Authority
DK
Denmark
Prior art keywords
compound
mmol
test
adenosine
anxiety
Prior art date
Application number
DK10813754.8T
Other languages
English (en)
Inventor
Tomoyuki Kanda
Junya Kase
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2474544(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of DK2474544T3 publication Critical patent/DK2474544T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Claims (4)

1. Thiazolderivat gengivet ved formlen (IC)
eller et farmaceutisk acceptabelt salt deraf til anvendelse i behandling og/eller forebyggelse af en angstlidelse.
2. Thiazolderivat eller det farmaceutisk acceptable salt deraf ifølge krav 1, til anvendelse i behandling og/eller forebyggelse af en angstlidelse udvalgt blandt panikangst, agorafobi, OCD, social fobi, posttraumatisk stress, specifik fobi og generaliseret angst.
3. Anvendelse af thiazolderivatet beskrevet i krav 1 eller det farmaceutisk acceptable salt deraf, til fremstilling af et middel til behandling og/eller forebyggelse af en angstlidelse.
4. Anvendelse ifølge krav 3, hvor angstlidelsen er panikangst, agorafobi, OCD, social fobi, posttraumatisk stress, specifik fobi eller generaliseret angst.
DK10813754.8T 2009-09-02 2010-09-02 Terapeutisk middel mod angstlidelser DK2474544T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009202894 2009-09-02
PCT/JP2010/064989 WO2011027806A1 (ja) 2009-09-02 2010-09-02 不安障害治療剤

Publications (1)

Publication Number Publication Date
DK2474544T3 true DK2474544T3 (da) 2017-10-02

Family

ID=43649340

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10813754.8T DK2474544T3 (da) 2009-09-02 2010-09-02 Terapeutisk middel mod angstlidelser

Country Status (31)

Country Link
US (1) US20120172362A1 (da)
EP (1) EP2474544B1 (da)
JP (1) JP5663485B2 (da)
KR (2) KR20170044768A (da)
CN (1) CN102482271A (da)
AU (1) AU2010290424C1 (da)
BR (1) BR112012004850A2 (da)
CA (1) CA2772922C (da)
CL (1) CL2012000533A1 (da)
CY (1) CY1119483T1 (da)
DK (1) DK2474544T3 (da)
DO (1) DOP2012000056A (da)
EA (1) EA023728B1 (da)
ES (1) ES2643840T3 (da)
GE (1) GEP20156225B (da)
HR (1) HRP20171418T1 (da)
HU (1) HUE036543T2 (da)
IL (1) IL218320A (da)
LT (1) LT2474544T (da)
MA (1) MA33619B1 (da)
ME (1) ME02877B (da)
MX (1) MX2012002529A (da)
NZ (1) NZ598754A (da)
PL (1) PL2474544T3 (da)
PT (1) PT2474544T (da)
RS (1) RS56401B1 (da)
SI (1) SI2474544T1 (da)
TN (1) TN2012000093A1 (da)
UA (1) UA113383C2 (da)
WO (1) WO2011027806A1 (da)
ZA (1) ZA201202347B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718808B2 (en) * 2003-12-26 2010-05-18 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
MA41090A (fr) * 2014-12-03 2017-10-10 H Lundbeck As Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
JOP20200093A1 (ar) 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216584T1 (de) 1992-07-08 2002-05-15 Kyowa Hakko Kogyo Kk Xanthine-derivate als antidepressiva
ES2264210T3 (es) 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
WO2000069464A1 (fr) * 1999-05-12 2000-11-23 Fujisawa Pharmaceutical Co., Ltd. Nouvelle utilisation
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
MXPA04002389A (es) 2001-09-13 2004-05-31 Schering Corp Combinacion de un antagonista del receptor de adenosian a2a y un antidepresivo o ansiolitico.
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
BRPI0411120A (pt) * 2003-06-10 2006-07-18 Kyowa Hakko Kogyo Kk método para tratar de um distúrbio de ansiedade, composição, agente para tratar de um distúrbio de ansiedade, e, usos de um composto e de um derivado de xantina
US7718808B2 (en) * 2003-12-26 2010-05-18 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
EP1894930A4 (en) * 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
JP5121453B2 (ja) * 2005-08-02 2013-01-16 協和発酵キリン株式会社 睡眠障害の治療および／または予防剤
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою

Also Published As

Publication number Publication date
IL218320A (en) 2016-06-30
WO2011027806A1 (ja) 2011-03-10
EP2474544A1 (en) 2012-07-11
HUE036543T2 (hu) 2018-07-30
BR112012004850A2 (pt) 2020-06-23
JPWO2011027806A1 (ja) 2013-02-04
EA201270360A1 (ru) 2012-09-28
AU2010290424C1 (en) 2016-02-18
SI2474544T1 (sl) 2017-11-30
RS56401B1 (sr) 2018-01-31
EP2474544B1 (en) 2017-07-12
EP2474544A4 (en) 2013-01-23
CA2772922A1 (en) 2011-10-03
CA2772922C (en) 2017-11-21
KR20170044768A (ko) 2017-04-25
AU2010290424A1 (en) 2012-04-19
KR20120047311A (ko) 2012-05-11
PL2474544T3 (pl) 2017-12-29
HRP20171418T1 (hr) 2017-11-03
ME02877B (me) 2018-04-20
CY1119483T1 (el) 2018-03-07
CN102482271A (zh) 2012-05-30
UA113383C2 (xx) 2017-01-25
MA33619B1 (fr) 2012-09-01
GEP20156225B (en) 2015-01-26
AU2010290424B2 (en) 2015-11-05
ES2643840T3 (es) 2017-11-24
IL218320A0 (en) 2012-04-30
ZA201202347B (en) 2015-11-25
EA023728B1 (ru) 2016-07-29
JP5663485B2 (ja) 2015-02-04
MX2012002529A (es) 2012-04-11
CL2012000533A1 (es) 2012-09-14
US20120172362A1 (en) 2012-07-05
TN2012000093A1 (en) 2013-09-19
PT2474544T (pt) 2017-10-03
NZ598754A (en) 2014-08-29
DOP2012000056A (es) 2012-06-30
LT2474544T (lt) 2017-10-25

Similar Documents

Publication Publication Date Title
EP2474543B1 (en) Therapeutic agent for mood disorders
CA2760048C (en) Thiazole compound and use in the treatment of motor disorders
DK2474544T3 (da) Terapeutisk middel mod angstlidelser
US20200247798A1 (en) Therapeutic agent for anxiety disorders
US9549921B2 (en) Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C